Literature DB >> 31676991

Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler.

Karl Bass1, Dale Farkas1, Worth Longest2,3.   

Abstract

The objective of this study was to optimize the performance of a high-efficiency pediatric inhaler, referred to as the pediatric air-jet DPI, using computational fluid dynamics (CFD) simulations with supporting experimental analysis of aerosol formation. The pediatric air-jet DPI forms an internal flow pathway consisting of an inlet jet of high-speed air, capsule chamber containing a powder formulation, and outlet orifice. Instead of simulating full breakup of the powder bed to an aerosol in this complex flow system, which is computationally expensive, flow-field-based dispersion parameters were sought that correlated with experimentally determined aerosolization metrics. For the pediatric air-jet DPI configuration that was considered, mass median aerodynamic diameter (MMAD) directly correlated with input turbulent kinetic energy normalized by actuation pressure and flow kinetic energy. Emitted dose (ED) correlated best with input flow rate multiplied by the ratio of capillary diameters. Based on these dispersion parameters, an automated CFD process was used over multiple iterations of over 100 designs to identify optimal inlet and outlet capillary diameters, which affected system performance in complex and unexpected ways. Experimental verification of the optimized designs indicated an MMAD < 1.6 μm and an ED > 90% of loaded dose. While extrathoracic depositional loss will be determined in future studies, at an operating flow rate of 15 L/min, it is expected that pediatric mouth-throat or even nose-throat aerosol deposition fractions will be below 10% and potentially less than 5% representing a significant improvement in the delivery efficiency of dry powder pharmaceutical aerosols to children.

Entities:  

Keywords:  active dry powder inhaler; aerosol delivery to children; high-efficiency aerosolization; inline dry powder inhaler; small particle aerosol

Mesh:

Substances:

Year:  2019        PMID: 31676991      PMCID: PMC7324282          DOI: 10.1208/s12249-019-1535-4

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  29 in total

1.  The CF salt controversy: in vivo observations and therapeutic approaches.

Authors:  R Tarran; B R Grubb; D Parsons; M Picher; A J Hirsh; C W Davis; R C Boucher
Journal:  Mol Cell       Date:  2001-07       Impact factor: 17.970

2.  Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.

Authors:  Jagdeep Shur; Sau Lee; Wallace Adams; Robert Lionberger; James Tibbatts; Robert Price
Journal:  AAPS J       Date:  2012-06-22       Impact factor: 4.009

3.  Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.

Authors:  Matthew S Coates; Hak-Kim Chan; David F Fletcher; Judy A Raper
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

4.  Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler.

Authors:  Matthew S Coates; Hak-Kim Chan; David F Fletcher; Herbert Chiou
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

5.  Validating CFD predictions of respiratory aerosol deposition: effects of upstream transition and turbulence.

Authors:  P Worth Longest; Samir Vinchurkar
Journal:  J Biomech       Date:  2006-03-14       Impact factor: 2.712

6.  Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model.

Authors:  Antje Below; Deborah Bickmann; Joerg Breitkreutz
Journal:  Int J Pharm       Date:  2013-01-17       Impact factor: 5.875

Review 7.  In silico models of aerosol delivery to the respiratory tract - development and applications.

Authors:  P Worth Longest; Landon T Holbrook
Journal:  Adv Drug Deliv Rev       Date:  2011-05-27       Impact factor: 15.470

8.  The Sophia Anatomical Infant Nose-Throat (Saint) model: a valuable tool to study aerosol deposition in infants.

Authors:  H M Janssens; J C de Jongste; W J Fokkens; S G Robben; K Wouters; H A Tiddens
Journal:  J Aerosol Med       Date:  2001

Review 9.  Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?

Authors:  A L Smith
Journal:  J Cyst Fibros       Date:  2002-12       Impact factor: 5.482

Review 10.  Origins of cystic fibrosis lung disease.

Authors:  David A Stoltz; David K Meyerholz; Michael J Welsh
Journal:  N Engl J Med       Date:  2015-01-22       Impact factor: 91.245

View more
  5 in total

1.  Near Elimination of In Vitro Predicted Extrathoracic Aerosol Deposition in Children Using a Spray-Dried Antibiotic Formulation and Pediatric Air-Jet DPI.

Authors:  Dale Farkas; Morgan L Thomas; Amr Hassan; Serena Bonasera; Michael Hindle; Worth Longest
Journal:  Pharm Res       Date:  2022-06-27       Impact factor: 4.200

2.  Advancement of the Infant Air-Jet Dry Powder Inhaler (DPI): Evaluation of Different Positive-Pressure Air Sources and Flow Rates.

Authors:  Connor Howe; Mohammad A M Momin; Dale R Farkas; Serena Bonasera; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2021-08-30       Impact factor: 4.580

3.  In Vitro Analysis of Nasal Interface Options for High-Efficiency Aerosol Administration to Preterm Infants.

Authors:  Connor Howe; Mohammad A M Momin; Karl Bass; Ghali Aladwani; Serena Bonasera; Michael Hindle; Philip Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2022-02-14       Impact factor: 3.440

4.  High-Efficiency Dry Powder Aerosol Delivery to Children: Review and Application of New Technologies.

Authors:  Karl Bass; Dale Farkas; Amr Hassan; Serena Bonasera; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2020-10-14       Impact factor: 3.433

Review 5.  Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications.

Authors:  Zhanying Zheng; Sharon Shui Yee Leung; Raghvendra Gupta
Journal:  Pharmaceutics       Date:  2021-02-01       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.